Lifecore Biomedical
LFCRLifecore Biomedical is a publicly traded CDMO with a 60-year legacy, uniquely combining sterile injectable fill-finish services with proprietary sodium hyaluronate production. The company serves a global clientele developing drugs, biologics, medical devices, and combination products, with a strong track record of regulatory approvals from the FDA and EU. Its strategic focus is on complex formulations and difficult processes, supported by a 'fear-no-challenge' culture and a phase-appropriate approach to program development.
LFCR · Stock Price
Historical price data
AI Company Overview
Lifecore Biomedical is a publicly traded CDMO with a 60-year legacy, uniquely combining sterile injectable fill-finish services with proprietary sodium hyaluronate production. The company serves a global clientele developing drugs, biologics, medical devices, and combination products, with a strong track record of regulatory approvals from the FDA and EU. Its strategic focus is on complex formulations and difficult processes, supported by a 'fear-no-challenge' culture and a phase-appropriate approach to program development.
Technology Platform
Integrated platform combining sterile injectable fill-finish CDMO services with proprietary fermentation-based manufacturing of pharmaceutical-grade Sodium Hyaluronate (NaHy) in a wide molecular weight range.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes with large, global CDMOs (e.g., Lonza, Catalent) in sterile injectables and with specialized hyaluronic acid producers (e.g., Galderma, Anika Therapeutics). Differentiation is achieved through deep, integrated expertise in sodium hyaluronate, a focus on complex formulations, and a strong regulatory track record.